First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL
Terminated · Phase 1 · NCT04401020
Conditions: Neoplasm Malignant
At a glance
- Research payments reported, 2025
- $340,907
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 47
About the trial
- Sponsor
- Sanofi
- Tested
- SAR442257 (drug)
- Dates
- Started 2020-07-24; completion 2026-05-11
- Results posted
- Not yet
Primary Objective: To determine the maximum tolerated dose (MTD) of SAR442257 administered as a single agent in patients with relapsed and refractory multiple myeloma (RRMM) and relapsed and refractory non-Hodgkin lymphoma (RR-NHL), and determine the recommended Phase 2 dose (RP2D) Secondary Objectives: * To characterize the safety profile of SAR442257 * To characterize the pharmacokinetics (PK) profile of SAR442257 * To assess preliminary evidence of antitumor activity
From ClinicalTrials.gov, last updated 2026-09-29. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $340,907 in research payments for this study in 2025 (13 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- City of Hope National Medical Ctr $209,373
- Office of Research Administration $131,534
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.